Stockwinners Market Radar for July 11, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Allegiant Travel reports total system June RPM up 12.9% - Allegiant Travel reports June total system RPM up 12.9%, total system passengers up 14.8%, total system available seat miles up 13.3%, load factor 84.9% vs. 85.2% last year.

18:58 EDT Fly Intel: After Hours Movers - HIGHER: Hookipa (HOOK) up 40.0% after disclosing FDA clearance of IND application for HB-201 clinical trial... Tallgress Energy (TGE) up 1.8% after raising dividend. DOWN AFTER EARNINGS: Illumina (ILMN) down 16.0% after below-consensus Q2 guidance and cutting FY19 outlook. Emcore (EMKR) down 15.8% after cutting Q2 guidance... Synacor (SYNC) down 11.2% after saying AT&T switching to new portal provider for ATT.net... Brookfield Infrastructure Partners (BIP) down 3.2% after quity offering... Spirit Airlines (SAVE) down 3.0% after Q2 guidance. ALSO LOWER: SenesTech (SNES) down 18.0% after equity offering... Innovative Industrial Properties (IIPR) down 5.0% after equity offering... Colgate-Palmolive (CL) down 0.5% after buying Filorga Cosmetiques skin care unit for $1.7B. Movers as of 18:45ET.

18:49 EDT Tellurian CEO: Cheap gas will create more demand - In an interview on CNBC's Mad Money, Tellurian CEO Charif Souki said: The best solution for Israel is to find ways to do business with their neighbors... We don't have any real competition... LNG has become a commodity and you have to be in the top quartile in terms of cost structure... The Permian producers don't understand what they're holding... The Permian has become the swing producer, so what happens in the U.S. is more important than OPEC.

18:39 EDT Allegiant Travel reports June RPM up 12.2% - Allegiant Travel reports June total system RPMs up 12.2%, total system passengers up 14.4%, total system available seat miles up 13.5%, load factor 85.9% vs. 86.9% last year.

18:11 EDT HeavenlyRx buys 25% stake in Jones Soda - International hemp and CBD company HeavenlyRx is pleased to announce an investment in Jones Soda Co. HeavenlyRx has acquired from Jones Soda 15M common shares, representing approximately 25% of the total issued and outstanding common shares of Jones Soda after giving effect to the issuance. As part of its investment, HeavenlyRx was issued a warrant to acquire 15M common shares that, if exercised, would increase HeavenlyRx's common share ownership of Jones Soda to approximately 39%. Additionally, from time to time prior to the exercise in full of the warrant, HeavenlyRx may purchase Jones Soda shares in the open market of up to 50% of the number of shares purchased upon partial exercise of the warrant.

18:05 EDT Synacor sinks 12% after saying AT&T switching to new portal provider for ATT.net - Shares of the company are down an additional 12% in after-hours trading to $1.34 per share.

17:34 EDT Granite Construction awarded $21M rail facility project in California - Granite Construction announced that it has been awarded a $21M contract by the San Bernardino County Transportation Authority for the Redlands passenger rail storage and maintenance facility project in San Bernardino, California. The contract was included in Granite's Q2 backlog. Granite will be responsible for the construction of the new storage and maintenance facility. This facility will support the Redlands passenger rail which is designed to connect residents, businesses and visitors to a variety of leisure, education, healthcare and other destinations. Scope of Granite's work includes building construction, underground utilities, demolition, earthwork, grading and concrete and asphalt paving. Construction is scheduled to begin in summer 2019 and is scheduled to be complete in winter 2020.

17:14 EDT General Dynamics awarded $173.81M Navy contract for submarine support - General Dynamics has been awarded a $173.81M cost-plus-fixed-fee contract for engineering, technical, design agent and planning yard support for operational strategic and attack submarines. The contract provides for drawings and related technical data; design change documentation; logistics technical data; configuration management; hull, mechanical and electrical engineering; submarine safety design review; non-propulsion plant electrical system engineering; propulsion plant engineering; maintenance engineering; refit/availability technical support; on-site support; configuration change program design and installation support; configuration change program material support; submarine technical trade support; training and facility support; research development test and evaluation program support; research and development submarine/submersibles support; miscellaneous special studies; temporary alteration support; modernization of submarine/submersible systems/subsystems and affordability/cost reduction technical support. Work is expected to be completed by September 2023. This contract includes options, which, if exercised, would bring the cumulative value of this contract to $1.04B and be complete by September 2023. FY19 other procurement; 2019 operations and maintenance and 2018 other procurement funding in the amount of $24.56M will be obligated at time of award, and $4.42M will expire at the end of the current fiscal year. In accordance with 10 U.S. Code 2304, this contract was not competitively procured. The Naval Sea Systems Command is the contracting activity.

16:45 EDT EMCORE trading resumes

16:41 EDT Illumina down 15% to $309.47 after lowering FY19 revenue outlook - The company also reported preliminary Q2 revenue of $835M, below consensus of $888.18M.

16:36 EDT Microsoft will terminate Internet Games services on Windows 7 by 2020 - In a blog posting, the Windows Gaming Team said: "Hello, Microsoft Internet Games players, it is with heavy hearts that we have made the difficult decision that the following games will no longer be supported.internet Backgammon -XP/ME, 7, Internet Checkers -XP/ME, 7,Internet Spades-XP/ME, 7,Internet Hearts-XP/ME Internet Reversi-XP/ME, and MSN Go-7 Microsoft Internet Games services on Windows XP and ME will end on July 31, 2019. Microsoft Internet Games services on Windows 7 will end on January 22, 2020."

16:33 EDT Coeur Mining reports Q2 gold production 86.6K oz - Reports Q2 silver output of 3.1M oz and zing output at 5.3M lbs. The company backs 2019 output guidance and expects to produce 334,000 - 372,000 ounces of gold, 12.2 - 14.7 million ounces of silver, 25 - 40 million pounds of zinc and 20 - 35 million pounds of lead.

16:27 EDT CarMax COO Edwin Hill sells over $419K shares of company stock - CarMax COO Edwin Hill disclosed in a filing that he had sold 4,792 shares of common stock at an average price of $87.49 per share on July 10. The total transaction value of the sale was $419,252

16:23 EDT AllianceBernstein reports preliminary AUM $581B as of June 30th - AllianceBernstein announced that preliminary assets under management increased to $581B during June 2019 from $560B at the end of May. The 3.8% increase was due to market appreciation, as well as total firmwide net inflows. By channel, Retail net inflows were partially offset by outflows from Institutions and Private Wealth.

16:21 EDT U.S. Xpress Enterprises updates Q2 and 2019 financial and CapEx guidance - U.S. Xpress Enterprises updated financial and capital expenditure guidance for Q2 and FY19. Based on current market conditions which continue to underperform original expectations, the company now expects its Q2 adjusted operating ratio to approximate 97.5%, vs. previous expectations of a sequential improvement from the 95.7% adjusted operating ratio generated in Q1. The company is also adjusting FY19 adjusted operating ratio guidance to a range of 95.5% to 97.5% vs. previous adjusted operating ratio guidance of 93.0%. CEO . Fuller stated, "In the current environment, we are tightly managing costs and adjusting our net capital expenditure budget for 2019 to a range of $110M-$130M vs. prior guidance of $170M-$190M. The net capital expenditure difference is expected to involve a combination of deferred tractor deliveries, and a reduction of the amount of planned replacement of leased equipment with owned. Overall tractor and trailer fleet age is not expected to change materially versus prior expectations".

16:19 EDT Intuitive announces transition of COO Sal Brogna - Intuitive announced Sal Brogna's intent to transition from his role as Executive Vice President and Chief Operating Officer. Brogna will remain with Intuitive through the end of 2019 and plans to serve as a consultant and advisor to the company starting in 2020. Brogna joined Intuitive in October 1999 and held a number of key roles in the organization over the course of his career, including Executive Vice President of Product Operations, Senior Vice President of Product Development and Vice President of Engineering. Prior to joining Intuitive, Brogna led design and development of complex robotic systems for commercial and industrial use.

16:16 EDT Palo Alto Networks names as new Chief Marketing Officer - Palo Alto Networks (PANW) announced the appointment of marketing veteran Jean English to the position of chief marketing officer. She will assume the role on August 1. She most recently served as senior vice president and CMO at NetApp (NTAP) for three years. Prior to that, she spent 17 years at IBM (IBM) in a variety of roles globally, including serving as the global vice president for IBM cloud marketing and leading the go-to-market transformation for IBM's cloud business.

16:13 EDT Cadiz says SB 307 will make water infrastructure solutions 'tougher to achieve' - The California State Assembly considered and passed Senate Bill 307, a measure designed to require additional state review of the Cadiz Water Project. The legislation will now move to Governor's Office for consideration. Governor Gavin Newsom has 12 days to either sign the measure or veto it. Cadiz issued a statement regarding the Assembly vote: "As our Governor has repeatedly emphasized, California continues to suffer from chronic water supply and affordable housing shortages. These problems are not unrelated. Solutions to these two critical problems depend on infrastructure improvements that are opposed at every turn. Bills like SB 307 will make solutions even tougher to achieve. An earlier version of the Cadiz Water Project was approved by the United States Department of the Interior in 2002. A revised Project underwent a decade of additional study, peer review, state environmental impact evaluation, a separate approval by San Bernardino County and was repeatedly validated by the California Courts. SB 307 is based on the false premise that the federal government never reviewed the Project and that CEQA, the County and the Courts were not fair and independent reviewers. Opponents have parlayed their considerable political influence to establish a new state review in a new forum sought by opponents after failing to succeed in all other venues. Joined by dozens of state and local organizations, we have expressed concern because SB 307 encourages infrastructure opponents to politicize project review and singles out one California Company and one project for unique treatment. Consequently, we will urge the Governor to veto SB 307. Should the bill be enacted however, Cadiz will embrace fair, open and transparent review of science. We are abundantly confident the Project is safe and sustainable. We have committed to 50 years of ongoing public scrutiny of the Project and agreed to the County's ongoing review and control of operations. We are also supportive of the announced efforts of Three Valleys Municipal Water District to initiate an inclusive study plan over coming months to further study mountain springs in the Project area. Any application for the finding required by SB 307 as a precondition to wheeling water through the Colorado River Aqueduct will be accompanied by clear and unequivocal data and reports that can withstand critical scrutiny. We will continue to go about our business of efficiently and sustainably farming our land, acting as responsible private stewards of a public resource. The Project will be lawfully progressed under all federal, state and local regulations. More than 10 billion gallons a year are wasted to the atmosphere each year from the Bristol and Cadiz Dry-Lakes. The Project would conserve this water and divert it to 400,000 people a year. More than 63 billion gallons have been irretrievably lost since the Project was first approved. If California is serious about meeting its commitment to provide, clean, reliable and affordable water to all people, of all color in all locations, Cadiz is ready to play its part."

16:09 EDT Invitae to acquire Jungla for approximately $50M - Invitae announced it has entered into a definitive agreement to acquire Jungla, a privately held company funded by Andreessen Horowitz that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests. The combination is expected to further enhance Invitae's genetic variant interpretation and ability to deliver high-quality, more affordable genetic testing for use in mainstream medical care. Separately, Invitae announced the addition of RNA analysis to its commercial testing, beginning with patients undergoing cancer testing. Under the definitive agreement, Invitae will acquire Jungla for approximately $50M upon closing, $35M of which shall be in Invitae common stock and $15M of which shall be in cash, subject to certain adjustments. In addition, Invitae will pay up to $15M upon the achievement of certain milestones, mostly in stock with the balance in cash. The acquisition is expected to close in the coming days, subject to customary closing conditions. Invitae has already factored in the additional operating expense of this acquisition in prior statements about expected 2019 cash burn.

16:07 EDT ICF International awarded IDIQ contract valued at up to $330M - The U.S. Navy recently awarded ICF a new multiple-award indefinite delivery, indefinite quantity contract to provide cyberspace technical, management and professional services. The company was one of a handful of qualified firms selected for this work. The multiple-award contract, which is with the Navy Information Warfare Center Pacific has a potential ceiling value of $800M over seven years, including one three-year base and two two-year options. The base period has a potential award value up to $330M.

16:07 EDT Gladstone Land buys 324 acres of farmland in Monterey Co, CA for $9M - Gladstone Land Corporation announced that it has acquired 324 gross acres of farmland in Monterey County, California, for $9.0M. The farm, located in Salinas, California, is used to grow strawberries and vegetables. In connection with the acquisition, the company also entered into a six-year, triple-net lease with Wish Farms, Inc.

16:06 EDT American Renal Associates applauds Trump administration's kidney executive order - American Renal Associates Holdings issued the following statement regarding the July 10, 2019, Executive Order by President Trump related to the Administration's Advancing American Kidney Health Initiative: "ARA applauds the Trump Administration and leadership at the Department of Health and Human Services, the Centers for Medicare and Medicaid Services (CMS) and the Center for Medicare and Medicaid Innovation (CMMI) for taking bold actions and advancing new policies that should significantly benefit the lives of more than 30 million Americans living with kidney disease. ARA supports the admirable goals of the Executive Order, which aims to increase awareness and prevention of kidney disease, encourage alternative treatment options, and dramatically increase kidney transplantation. ARA's executive leadership team, including Chairman and Chief Executive Officer Joe Carlucci and Executive Vice President and Chief Operating Officer Dr. Don Williamson, were honored to be present in Washington, D.C. to witness President Trump sign the historic Executive Order. ARA believes that the End-Stage Renal Disease Treatment Choices (ETC) mandatory model will offer opportunities for physicians and caregivers to facilitate increased patient choice for home dialysis and transplantation. ARA is also encouraged by CMMI's approach to offer to kidney care community participants multiple options to participate in value-based care for Chronic Kidney Disease and End Stage Renal Disease patients through the Kidney Care First (KCF) and Comprehensive Kidney Care Contracting (CKCC) Models. Our organization looks forward to CMS's rule-making process for the ETC mandatory model, and intends to evaluate the optional models with a view to participating in one or more of these new models beginning in 2020. ARA is particularly grateful that HHS and CMS leadership engaged widely with the kidney care community to develop these policies, and our organization looks forward to further engagement as these policies and CMMI models are being advanced. ARA is confident that its physician partnership-based operating model, outstanding clinical performance and integrated approach to patient care should position the Company well to support the Trump Administration's goals of improving the lives of kidney care patients."

16:03 EDT Alaska Air reports combined June traffic up 1.0% - Alaska Air reported a 1.7% increase in traffic on a combined basis for all operations, on a 1.9% increase in capacity compared to June 2018. Load factor decreased 0.1 points to 88.2%.

15:26 EDT Twitter is down or not working according to down detector - According to the report "can't log in or send tweets." Reference Link

15:22 EDT Twitter reported to be experiencing service disruption - According to the service "downrightnow" and other reports, Twitter "may be experiencing issues right now." Reference Link

14:30 EDT G-III Apparel CEO acquires 40,000 common shares - In a regulatory filing, G-III Apparel CEO Morris Goldfarb disclosed the acquisition of 40,000 common shares of the company at a price of $26.47 per share.

14:03 EDT Ascent Capital announces suspension from Nasdaq effective July 12 - Ascent Capital Group announced that it has received notice from The Nasdaq Stock Market that Ascent's Series A common stock will be suspended from trading on NASDAQ at the open of business on Friday, July 12. Ascent continues to intend to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on Monday, July 15, as previously disclosed. Ascent has also announced that its Series A common stock is currently quoted on the OTC Markets under the symbol "ASCMA."

13:16 EDT Google says language reviewer leaked confidential Dutch audio data - David Monsees, Search Product Manager at Google, said that the company has recenty learned that a language expert reviewer has violated its data security policies by leaking confidential Dutch audio data. "Our Security and Privacy Response teams have been activated on this issue, are investigating, and we will take action," Monsees said in a blog post. "We are conducting a full review of our safeguards in this space to prevent misconduct like this from happening again." "The Google Assistant only sends audio to Google after your device detects that you're interacting with the Assistant-for example, by saying "Hey Google" or by physically triggering the Google Assistant," he continued. "A clear indicator (such as the flashing dots on top of a Google Home or an on-screen indicator on your Android device) will activate any time the device is communicating with Google in order to fulfill your request. Rarely, devices that have the Google Assistant built in may experience what we call a "false accept." This means that there was some noise or words in the background that our software interpreted to be the hotword (like "Ok Google"). We have a number of protections in place to prevent false accepts from occurring in your home." Reference Link

13:04 EDT Motorola Solutions acquires mobile video solutions firm WatchGuard - Motorola Solutions announced it has acquired WatchGuard, "a U.S. leader in mobile video solutions," the company said. Terms of the transaction were not disclosed. WatchGuard designs and manufactures in-car video systems, body-worn cameras, evidence management systems and software. Its solutions enable law enforcement users to capture, manage, store and share high-quality video evidence. The company manufactures its products at its Texas headquarters. "An integrated, secure mobile video solution can enhance safety and efficiency for public safety users," said John Kedzierski, senior vice president, Video Security Solutions, Motorola Solutions. "WatchGuard provides industry-leading capabilities, from capturing an incident from more than a dozen vantage points to technology that enables users to recover and upload video from events hours or days after they happened." The acquisition expands Motorola Solutions' mission-critical ecosystem, adding to its video security solutions platform that includes fixed cameras and advanced analytics from Avigilon and license plate recognition, LPR,cameras and software from Vigilant Solutions. "We are excited to join the Motorola Solutions team," said Robert Vanman, founder, chief executive officer and chairman, WatchGuard. "This acquisition enables us to continue providing market-leading mobile video solutions to existing customers while also leveraging Motorola Solutions' global footprint and growing video security solutions portfolio

12:55 EDT VW, Ford to provide update on global collaboration tomorrow - In a tweet, Volkswagen Group (VWAGY) said CEO Herbert Diess and Ford (F) president and CEO Jim Hackett will provide an update on their global collaboration tomorrow at 8:00 am ET. Reference Link

12:40 EDT On Deck Capital moves higher after announcing pact with Coast Capital Savings - Earlier today, Coast Capital Savings, Canada's largest credit union by membership, and OnDeck Canada, an online lender to Canadian small businesses, announced an innovative partnership aimed at accelerating online lending to Coast Capital small business members. Beginning this month, Coast Capital Savings small business members can apply for term loan financing from OnDeck of up to CAD $250,000 online, in branch or through the Coast Capital Contact Centre and receive approval and funding in as little as one day. The agreement is aimed at bridging a gap in small business credit in Canada by addressing the urgent needs of Canada's small business sector for faster short-term financing. The partnership with OnDeck Canada will help Coast Capital as they expand nationally, positioning the credit union as a leader in small business banking with a best-in-class suite of products and services. OnDeck Canada is part of OnDeck Capital,an online small business lender. OnDeck pioneered the use of data analytics and digital technology to make real-time lending decisions, delivering funds rapidly to small businesses online. Since inception, OnDeck Canada has originated over CAD $440 million in funding to small businesses in Canada. "By partnering with OnDeck Canada, Coast Capital is now able to offer a seamless member experience that is both fast and incredibly easy," explains Derek Turner, Head of Small Business, Coast Capital Savings. "As a purpose-driven and member-owned federal credit union, we are in a unique position to help small business members improve their financial well-being. Today's announcement is an integral part of our always expanding offerings for our existing and future small business members that will see new and innovative products and services brought to market to serve this very important segment." Shares of On Deck are up 3.26% or 13c to $3.95 per share in early afternoon trading.

12:12 EDT Cemtrex jumps over 11% after announcing software development of Arcadium - Earlier today, Cemtrex announced it has developed for luxury brands housed under Richemont, Arcadium - an upcoming immersive augmented reality experience featuring seven innovative experiences. Arcadium's augmented reality experience is custom engineered and designed by Cemtrex for Cartier, Jaeger-LeCoultre, Montblanc, Officine Panerai, Piaget, Vacheron Constantin and IWC Shaffhausen. The experiences will be unveiled in New York City's Hudson Yards on July 11, 2019. We are thrilled to showcase these groundbreaking AR experiences." said Saagar Govil, CEO and Chairman of Cemtrex. "This project aligns perfectly with our mission to create revolutionary experiences through technology and gives us an amazing platform to showcase our innovative team of designers and developers. We believe this experience will pioneer how retail companies utilize Augmented Reality to transcend their brands into the digital future. We believe this project represents the first of many opportunities to collaborate with leading brands that want to differentiate themselves through technology for years to come." Shares of the company are up 11.17% or 24c to $2.39 per share in midday trading.

12:00 EDT Mallinckrodt falls -7.5% - Mallinckrodt is down -7.5%, or -66c to $8.05.

12:00 EDT Circor falls -9.1% - Circor is down -9.1%, or -$4.13 to $41.28.

12:00 EDT AAR Corp. rises 9.9% - AAR Corp. is up 9.9%, or $3.88 to $43.09.

11:20 EDT Valet Living acquires WasteRetriever, terms not disclosed - Valet Living acquires doorstep trash and recycling collection company, WasteRetriever. Valet Living's interest in WasteRetriever stems from many parallels between the two companies, including alignment on core values. WasteRetriever currently services approximately 30,000 apartment homes in 9 states, all of which will move to the Valet Living portfolio. WasteRetriever has approximately 150 associates including its founder, John Lis, will transition to become Valet Living associates. Valet Living is a portfolio company of the Private Equity Group of Ares Management, L.P. and Harvest Partners, LP.

10:49 EDT Twitter to use Canada as testing ground for hiding replies to tweets - Twitter said in a blog post, "Starting next week, people in Canada will have the option to hide replies to their Tweets. Anyone around the world will be able to see and engage with hidden replies by tapping the grey icon that will appear. We want to be clear and transparent when someone has made the decision to hide a reply, and will be looking at how this feature gives more control to authors while not compromising the transparency and openness that is central to what makes Twitter so powerful. By testing in one country we want to get feedback and better understand how this tool can improve before it's available globally." Twittter acknowledged that "distracting, irrelevant, and offensive replies can derail the discussions that people want to have." Reference Link

10:41 EDT Powell says 'too early to say' if Facebook 'too big' to build digital currency - Fed Chair Jerome Powell said the central bank is "at the very beginning of assessing" Facebook's plans regarding the Libra digital currency.

10:26 EDT Powell says Facebook's Libra 'raises a lot of serious concerns' - Federal Reserve Chair Jay Powell is back on Capitol Hill this morning to testify before the Senate Banking Committee.

10:14 EDT Redfin partners with Opendoor in Phoenix and Atlanta - Opendoor and Redfin (RDFN) earlier today announced that home sellers in Phoenix and Atlanta can now request an Opendoor offer through Redfin's site and mobile apps. "By coming together, Opendoor and Redfin are giving homeowners more options for selling their home in a simple and convenient way. Redfin will also continue to expand RedfinNow, its own instant offer service," the company said in a statement.

10:03 EDT Schneider National appoints Thom Jackson as EVP, general counsel - Schneider (SNDR) announced that Thom Jackson has joined the company as EVP and general counsel. He succeeds Paul Kardish, who left the organization in March 2019. Prior to joining Schneider, Jackson served as SVP, general counsel and secretary of Knowles Corporation (KN), an electronic audio component manufacturer.

10:00 EDT Circor falls -5.7% - Circor is down -5.7%, or -$2.57 to $42.84.

10:00 EDT NIO Inc. falls -7.1% - NIO Inc. is down -7.1%, or -26c to $3.42.

10:00 EDT Bitauto rises 8.4% - Bitauto is up 8.4%, or 96c to $12.41.

09:50 EDT KAR Auction mentioned cautiously at Off Wall Street

09:19 EDT Jaguar Health subsidiary Napo agrees to support crofelemer study - Jaguar Health announced that its wholly owned subsidiary, Napo Pharmaceuticals, has agreed in principal to support a U.S.-based university's request to begin an "Institution Initiated Clinical Research Study." The university will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in non-HIV patients, Jaguar said in a statement. The study has received approval from the University's Institutional Review Board, and Napo Pharmaceuticals is currently negotiating the definitive agreement with the university, it added.

09:13 EDT GrowLife receives patent issuance on design of commercial cloning system - GrowLife announced that the Canadian patent regulatory authority issued the Company a patent on the design of its EZ-CLONE Pro Commercial Cloning System entitled "Aeroponics System with Rack and Tray" under patent number 2,985,009. The product was developed by GrowLife's recently majority acquired EZ-CLONE Enterprises, Inc. which specializes in the manufacturing of cloning and propagation equipment. The newly patented design was developed for commercial plant cultivators in the hemp and marijuana industries to provide a sustainable, user-friendly way to fill the growing demand for clones.

09:08 EDT Lightbridge awarded patents in Europe, Eurasia for CANDU fuel assembly - Lightbridge Corporation announced that it has separately received Notices of Allowance from the European Patent Office and the Eurasian Patent Convention, which includes Russia and other territories across Eurasia, for another key patent relating to its innovative metallic fuel design. These latest patents provide protection in Europe and Eurasia for a fuel assembly design incorporating multi-lobe metallic fuel rods for use in CANDU heavy water reactors. According to the World Nuclear Association, there are 49 CANDU-type pressurized heavy water reactors currently in use around the world.

09:06 EDT 3D Systems awarded $15M contract by Army Research Laboratory, - 3D Systems has been awarded a $15M contract by the Combat Capabilities Development Command Army Research Laboratory, also known as ARL, to create the world's largest, fastest, most precise metal 3D printer. 3D Systems and the National Center for Manufacturing Sciences will partner with ARL and the Advanced Manufacturing, Materials, and Processes Program. The printer's build envelope is planned to be 1000mm x 1000mm x 600mm, with ability to build minimum wall thickness of 100microm and layer thickness of 30microm. This is a significant increase over current large-scale metal 3D printers with a build envelope of 500mm x 500mm x 500mm.

09:05 EDT DXC Technology expands strategic partnership with Microsoft - DXC Technology (DXC) announced the expansion of its strategic partnership with Microsoft (MSFT) through the formation of a global Microsoft Azure Digital Transformation Practice to accelerate client migration to the Microsoft Azure public cloud with greater efficiency and agility. The DXC and Microsoft Azure Digital Transformation Practice will focus on helping organizations manage the pace of technology change by bringing greater agility to the creation and execution of public cloud strategies.

09:04 EDT Generex acquires Pantheon Medical Foot & Ankle, terms not disclosed - Generex Biotechnology Corporation announced that the company has completed the acquisition of Pantheon Medical - Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, real estate, and an FDA letter related to balanced plating system, on a debt free basis, in a non-cash transaction with Generex stock, plus additional cash and stock consideration upon achieving certain sales and profit goals. Pantheon Medical - Foot & Ankle is a multi-million dollar company that began operations in 2014 with a physician friendly, "all-in-one", integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, the Company will be developing and submitting several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System.

09:03 EDT OpenText, MasterCard announce partnership - OpenText (OTEX) and Mastercard (MA) announced a partnership to help companies increase financial efficiencies across global supply chains, starting in the automotive industry. The collaboration will further advance a connected and scalable digital ecosystem, allowing companies irrespective of size, location or technical capability to build increased trust and security into trading partner relationships. The new solution from OpenText and Mastercard aims to increase the speed, compliance and security for business information, payments and financing in the automotive supply chain. It is designed to facilitate integrated payments and to enhance the management of vendor master data, enabling suppliers to better manage risk for trade finance, accelerate cash flow for outstanding invoices and secure financial transactions with enhanced digital identity. The integrated OpenText and Mastercard offering will also provide OpenText Business Network customers the ability to access spot financing through the Mastercard Track B2B global trade enablement platform. It will leverage the OpenText Supplier Portal, the OpenText Identity Portal and the OpenText IoT Platform, integrated with Mastercard's financial partners.

09:02 EDT Diana Shipping increases puchase price to be paid in tender offer - Diana Shipping announced that the Company has increased the purchase price to be paid in its tender offer to purchase up to 2,000,000 shares, or about 2.0%, of its outstanding common stock using funds available from cash and cash equivalents to US$3.75 per share and extended the Offer until the end of the day, 5:00 P.M., Eastern Time, on July 25, 2019, to allow additional time for stockholders to tender their shares. Except as set forth herein, the terms and conditions of the Offer remain the same. Computershare Trust Company, N.A., the depositary for the Offer, has advised the Company that as of the close of business, New York City time, on July 10, 2019, the last business day prior to the announcement of the extension of the Offer, 3,966 shares have been validly tendered pursuant to the Offer and not properly withdrawn.

09:00 EDT American Lithium expands TLC project to 4,000 acres - American Lithium provides an update on its TLC sedimentary lithium project located just 12 kilometers from the regional mining centre of Tonopah, Nevada. Highlights: Drilling: Core samples from 5 drill holes confirm stratigraphic and extension of mineralized lithium horizon over 6 square kilometers. An additional 5 reverse circulation drill holes have been permitted and the Company is waiting for drill rig availability to drill these holes. Assay results for the core holes are pending. Processing: 2nd phase leach testing returned exceptional results indicating a 90% Lithium extraction in 10 minutes with a fifty percent reduction in reagent consumption. The results confirmed continuous process capability for lithium recovery at scale. The Company therefore believes processing scalability will not limit the scope or size of a proposed mining operation. Permitting: The Company has strategically expanded its acreage position to 1650 ha or 4,000 acres in 200 lode claims. Resource Study: Company has engaged renowned sediment hosted lithium expert, Jerry Aiken, to produce a maiden lithium resource estimate. Preliminary mineralogy indicates dominance of lepidolite. Mass balance suggests significant free lithium in addition to the lithium present in the lepidolite. Milestones: American Lithium officially moves from exploration into resource delineation drilling. Company establishes geological and permitting field office and sample processing facility in Tonopah Nevada. Counter-current leach tests initiated. Focus on reagent consumption, temperature and resulting economics. Commencement of environmental studies towards a Plan of Operations. Completes all required spring season biological surveys. Engages Nevada Water Resource Professional to validate water availability as preliminary investigations indicate multiple sources with adequate capacity.

08:52 EDT Xebec announces inclusion in DOE project to enable biomethane production - Xebec Adsorption announced its inclusion in the U.S. Department of Energy's $24M commitment to a public-private collaboration funding 77 energy technology projects. Rhe Office of Technology Transition's Technology Commercialization Fund will advance the commercialization of promising energy technologies and strengthen partnerships between DOE's National Laboratories and private sector companies to deploy these technologies to the marketplace. Xebec's a supporting Industrial partner on this project as a result of its collaboration with Southern California Gas, and a California treatment facility. The project is being conducted through Lawrence Livermore National Laboratory by lead researcher Sarah Baker. This $500,000 grant to the Lawrence Livermore National Laboratory will be used to develop and seek to commercialize their composite sorbent technology to more effectively remove CO2 from biogas. This proposed technology has the potential for significant improvements over the current state-of-the-art adsorbents used for biogas upgrading. Xebec will play an advisory role with expertise in sorbents and biomethane production.

08:48 EDT XBiotech announces Seth Forman to chair second Phase 2 study of bermekimab - XBiotech announces that Seth Forman, M.D., will Chair the Company's upcoming randomized, double-blind, placebo controlled Phase 2 study in Atopic Dermatitis. This second Phase 2 study of bermekimab to treat moderate to severe AD in adults will build on results of a recently completed randomized study that showed rapid improvement in inflammatory lesions and pruritus. Forman is Board Certified in Dermatology and Dermatopathology. Forman was a principal investigator in XBiotech's recent open label study which demonstrated that weekly treatment with bermekimab resulted in rapid and significant improvement of disease in patients with moderate to severe AD. The following outcomes were demonstrated in the study: After only eight weeks of treatment, patients achieved the following clinically significant results: 75% of patients, EASI 75; 80% of patients, reduction in overall pain greater than or equal to4 points; 75% of patients, a reduction in overall itch greater than or equal to4 points;79% of patients, a reduction in anxiety score greater than or equal to4 point; 75% of patients, a reduction in depression score greater than or equal to4 points. In addition, after only four weeks of treatment, patients treated with bermekimab had already achieved the following: 66% reduction in skin lesions, as measured by the Eczema Area and Severity Index ; 57% reduction in worst itch, as measured by the Numerical Rating Scale for Itch ; 61% reduction in worst pain, as measured by the Numerical Rating Scale for Pain.

08:42 EDT BIO-key raises $2.55M in private placement of Senior Secured Convertible Note - BIO-key International announced the sale of a $3.06M Senior Secured Convertible Note to Lind Global Macro Fund, LP. At closing, $2.55M was funded, with the proceeds to be used for general working capital purposes, including repayment of outstanding indebtedness. The Note is secured by a first priority lien on substantially all of BIO-key's assets and properties and is convertible at the option of the Investor into shares of BIO-key common stock at a fixed conversion price of $1.50 per share. The principal amount of the Note is due and payable as follows: $918,000 is due 180 days after funding; $1,071,000 is due 270 days after funding, and the balance is due 12 months after the date of funding. BIO-key has the right to prepay the Note in full at any time without penalty, in which case the Investor will have the option of converting 25% of the outstanding principal amount of the Note into BIO-key shares at $1.50 per share. Additionally, the Investor was issued a five-year warrant to purchase 2,000,000 shares of common stock at a fixed exercise price of $1.50 per share. The Warrant is immediately exercisable.

08:40 EDT ABM initiates Energy Performance Contracting program for Aiken County schools - ABM has initiated an Energy Performance Contracting program for Aiken County Public Schools in Aiken County, South Carolina. ABM's customized solution is projected to save Aiken County Public Schools more than $70M in energy and operating costs over a 20-year period. Revenue from savings will address aging infrastructure needs, while also providing budget relief.

08:37 EDT T. Rowe Price reports preliminary AUM $1.13T at June 30 - Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $3.2B in June, and $5.9B for the quarter-ended June 30. This brings total client transfers for the year-to-date period ended June 30 to $12B.

08:36 EDT Q BioMed says remains 'confident in bringing' Strontium-89 to market this year - Q BioMed gave an update on its non-opioid therapy for the debilitating pain associated with metastatic skeletal cancer. The company said, "We have been working hard to commercialize both our Strontium-89 products. In addition to the global exclusive license to generic Strontium-89 from BioNucleonics Inc., we accelerated our global commercial launch by purchasing the Metastron brand from GE Healthcare in November of 2018. As a result, we now control significant market share for this injectable non-opioid metastatic cancer palliation drug in North America and much of the world. MetastronTM is approved for sale in 22 countries as a non-opioid therapy for the debilitating pain associated with metastatic skeletal cancer. As part of the Metastron acquisition, we agreed to transition manufacturing to another facility and chose IsoTherapeutics to be that manufacturer in parallel with our Strontium-89 product. 'The FDA approval of IsoTherapeutics to produce a commercial drug product is one of several milestone catalysts we expect to positively impact our business over the next few months," stated CEO Denis Corin. 'Our Strontium-89 products are our lead revenue opportunities and an important step for both Q BioMed and the many patients that will benefit from finally having access to the non-opioid palliation treatments. Once the FDA approves IsoTherapeutics Group, this radiopharmaceutical is well positioned to generate revenues in 2019 and beyond.' Although the commercial manufacturing approval process has taken longer than anticipated, we are now more confident than ever in the timing around the commercial launch. Our contract manufacturer expects to complete the final site modifications required by the FDA after its recent inspection by the end of the month, after which, a follow up review may be required to approve the application. As disclosed earlier this year, the licensor, BioNucleonics, of our generic Strontium-89 product refused to transfer outright ownership of the amended new drug application after we performed fully on our obligations. We determined that only a court order would successfully compel BNI to perform and we are confident that will occur in 2019. Thankfully, the BNI legal activity has had no material impact on the timing around the approval of our contract manufacturer, IsoTherapeutics Group LLC to be a producer of a commercial drug product. We expect that process to be completed shortly. Thus, we remain confident in bringing a Strontium-89 product to market this year. Our Strontium-89 radiopharmaceutical drug products are expected to begin generating revenue this year in the cancer pain palliation market, with a significant opportunity to expand into a much larger market through our planned phase IV clinical trial designed to expand the label from a pain palliation to a cancer therapeutic."

08:34 EDT Alnylam CFO Manmeet Soni to resign, Jeff Poulton to succeed - Alnylam announced that Jeff Poulton is joining the company and has been appointed executive VP and CFO, effective August 13. Poulton will join Alnylam with nearly 25 years of financial, operational and strategic leadership experience. Manmeet Soni has decided to resign to pursue other interests; he will continue as CFO of Alnylam through August 12. Poulton was most recently CFO of Indigo, a company dedicated to harnessing nature to help farmers sustainably feed the planet.

08:33 EDT Marrone Bio, Valagro announce research collaboration - Marrone Bio Innovations announced that it has entered into a strategic partnership to collaborate on research and development efforts with Valagro. The global, non-exclusive research collaboration will leverage a subset of Marrone Bio's collection of 18,000 microorganisms in conjunction with Valagro's biostimulant and plant nutrition products that enhance crop yield and quality. Products resulting from this partnership have the potential to enhance a grower's productivity and return on investment with plants that develop better root systems, grow with more vigor and thrive under harsher growing conditions. Additonally, growers of specialty crops would have the potential to produce higher quality fruit that matures more quickly.

08:31 EDT ATIF Holdings announces $1.6M financial consulting service agreement - ATIF Holdings announced that it had entered into a financial consulting service agreement to act as a financial advisor for Shenzhen Micro Union Gold League Electronic Commerce Technology. The agreement was signed in anticipation of MUGL's entrance into the U.S. capital market. Pursuant to the Agreement dated July 8, 2019, ATIF agreed to provide services including business consulting, capital market advising for business planning and strategy development, planning and assisting with fund raising activities, and investor and public relations services. As consideration, MUGL agreed to pay the Company a fixed consulting fee of $1.6 million, to be paid in installments and subject to certain conditions.

08:26 EDT AC Immune reports initial interim data from Phase 1b trial of ACI-24 vaccine - AC Immune announced initial interim data from an ongoing Phase 1b trial of the ACI-24 anti-Abeta vaccine to treat Alzheimer's disease like symptoms in subjects with Down syndrome as well as key takeaways from its Key Opinion Leader meeting, held in New York City. The event is being co-chaired by Professor Pfeifer and Professor William Mobley, Executive Director of the University of California San Diego's Down Syndrome Center for Research and Treatment. It features presentations from Professor Mobley and Dr. Brian Skotko, Associate Professor at Harvard Medical School and the Emma Campbell Endowed Chair on Down Syndrome and Director of the Down Syndrome Program at Massachusetts General Hospital, as well as Professor Pfeifer and Dr. Marie Kosco-Vilbois, Chief Scientific Officer of AC Immune. Highlights of Dr. Skotko's presentation include: DS is caused by having a third copy of chromosome 21 and occurs in 1/~792 live births; ~5,000 children per year, ~212,000 people living with DS in the US and ~359,000 in Europe; Adults with DS are increasingly moving into semi-independent living situations and securing paid employment, are involved in romantic relationships and marry, participate in day habilitation services or are active participants in sports. Initial symptoms are typically changes in behavior; seizures can also be an early warning sign, followed by memory loss Based on surveys, family members and people with DS say they are satisfied, even positive, about their lives despite acknowledging the challenges that accompany DS. Highlights from Professor Mobley's presentation include: The neuropathological changes in DS subjects are very similar but not identical to typical AD. People with Down syndrome have an extra copy of chromosome 21, which houses the gene that codes for amyloid precursor protein. APP is the parent protein of Abeta, a protein fragment that accumulates into amyloid plaques, a key feature of AD; Studying AD-like symptoms in the DS population addresses many of the key dilemmas that hinder the discovery of new treatments: uncertain mechanisms and timing of disease-induced brain changes, difficulty offering treatment before disease onset, genetic and age-related variability, and the risk of including subjects with other forms of age-related dementia; For AD in DS, the disease mechanism and approximate timing of onset are known; readily detectable pathological changes occur prior to AD-like symptoms, enabling treatment prior to disease onset; the DS population is far more homogeneous and carries minimal risk of having coexisting conditions causing dementia at such a young age; In mouse models of DS, vaccination against Abeta by ACI-24 improved cognition and prevented neuronal atrophy.

08:20 EDT Atreca appoints Lisa Decker as CBO, Courtney Phillips as general counsel - Atreca (BCEL) announced the appointment of Lisa Decker, Ph.D., as chief business officer and Courtney Phillips as general counsel. As CBO, Dr. Decker will lead Atreca's corporate development function, including its strategic partnering initiatives and alliance management. Prior to joining Atreca, she served as the VP of Business Development at Nektar Therapeutics (NKTR). As general counsel, MPhillips will lead Atreca's legal, compliance and intellectual property functions. Prior to joining Atreca, Phillips was the VP of Corporate Law at Global Blood Therapeutics (GBT).

08:16 EDT Eli Lilly announces general counsel Mike Harrington to retire at end of year - Eli Lilly and Company announced several changes to the company's executive committee. Mike Harrington, senior vice president and general counsel, will retire at the end of the year. Christi Shaw, senior vice president and president Lilly Bio-Medicines, has announced she will leave Lilly at the end of August. Patrik Jonsson, currently president and general manager of Lilly Japan, will succeed Shaw. A search is underway for Harrington's successor.

08:14 EDT Actinium's Iomab-B AML treatment shows minimal radiation exposure to caregivers - Actinium Pharmaceuticals presented the findings of two studies that support the safety of healthcare professionals who provide care to patients treated with Iomab-B, Actinium's lead product candidate, which is being studied in the pivotal Phase 3 SIERRA trial. The findings were presented at the Health Physics Society 64th Annual Meeting held July 7th-11th in Orlando, Florida. The studies evaluated radiation exposure to healthcare professionals who cared for patients treated with Iomab-B and the exposure from handling blood samples from patients following Iomab-B infusion. Both studies reported minimal radiation exposure to the respective healthcare professionals. The SIERRA trial is a multicenter, 150 patient study for patients with active, relapsed or refractory AML or Acute Myeloid Leukemia that is the only randomized Phase 3 trial to offer a potentially curative BMT to this patient population for which there is no standard of care. Radiation exposure levels to all staff were found to be minimal, with mean cumulative exposure of 0.09 mSv, contributing minimal exposure to the 50 mSv annual occupational limit.

08:12 EDT Aimmune cautions stakeholders on ICER report on treatments for peanut allergy - Aimmune cautioned stakeholders against drawing conclusions from the Institute for Clinical and Economic Review's, or ICER's, final report on emerging desensitization treatments for peanut allergy. The company said, "In its review, ICER fails to incorporate available data on both long-term outcomes and quality-of-life. ICER's analysis and the public meeting discussion discounted patient and community perspectives on the physical, social and psychological benefits of desensitization. The resulting final report is biased against immunotherapy, generally, and fails to specifically capture the full value of AR101. Aimmune joins advocates and clinical experts asking payers and policymakers to engage in more thoughtful, unbiased consideration of available evidence-including patient perspectives on quality-of-life improvements and relief from the stress and fear of accidental exposure-when evaluating emerging treatments for peanut allergy. In clinical trials, AR101, Aimmune's investigational biologic drug for use in oral immunotherapy, has demonstrated the ability to increase the median tolerated dose of peanut protein by 100-fold in each of its two pivotal Phase 3 clinical trials. While the report found AR101 to be cost-effective well below traditional health economic thresholds, ICER failed to acknowledge the availability of the positive long-term efficacy and quality-of-life data from the PALISADE open label follow-on study, as well as the clinical outcomes data from the European Phase 3 ARTEMIS trial. These data were recently presented at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress and shared with ICER in May under its "academic in confidence" policy and throughout the review process including the June 11 public meeting. ICER did not acknowledge or incorporate the existing data in its final evidence report or the associated cost-effectiveness analysis. Additionally, ICER failed to consider the potential for long-term disease modification consistent with allergen immunotherapies and mischaracterized the allergic response associated with immunotherapy as a harm, rather than an expected, well understood and easily managed part of the immunotherapy process. With all immunotherapy, allergic reactions are expected and acceptable in the short term in exchange for long-term desensitization to protect against accidental exposure. In clinical trials, median tolerated dose for AR101-treated patients improved from 10mg at baseline to 1000mg at month 12 to 2000mg at month 18-demonstrating both the potential for long-term disease modification and the potential for significant protection against the average real-world reaction-provoking exposure of 125mg, or half a peanut." The FDA's Allergenic Products Advisory Committee, or APAC, will review Aimmune's biologics license application, or BLA, for AR101 at its meeting scheduled for September 13. The FDA accepted the BLA for AR101 in March and previously informed Aimmune that completion of its review would be targeted by late January 2020.

08:08 EDT Walgreens Boots Alliance, kaleo expand collaboration to include AUVI-q EAI - Walgreens and kaleo, a privately-held pharmaceutical company, announced AUVI-q auto-injector is available at Walgreens locations nationwide. AUVI-q is the first and only epinephrine auto-injector, or EAI, approved by the FDA for infants and toddlers weighing 16.5-33 pounds. Through this collaboration, Walgreens is the first national retail pharmacy to offer the entire AUVI-Q auto-injector product line, which also includes AUVI-Q 0.3 mg and 0.15 mg doses. As supply issues related to epinephrine auto-injector products by other manufacturers continue, the collaboration aims to broaden access to an available treatment option for patients with life-threatening allergies, especially as families prepare for back-to-school season. AUVI-Q is a prescription medicine approved by the FDA to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.

08:07 EDT BioTime initiates dosing in Phase I/IIa clinical study of OpRegen - BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System as well as with a new Thaw-and-Inject formulation of OpRegen, the company's retinal pigment epithelium transplant therapy, in its ongoing Phase I/IIa clinical study for the treatment of dry age-related macular degeneration, a leading cause of adult blindness in the developed world.

08:05 EDT Internap's iWeb Technologies wins multi-year deal with Loto-Quebec - Internap Corporation and Loto-Quebec, a Quebec government corporation operating a public lottery and other games of chance, announced a multi-year deal for network and infrastructure protection services. iWeb was selected through a RFP process as the provider who could deliver a proof-of-concept for a secure and effective solution that met all Loto-Quebec's needs.

08:05 EDT Leap Therapeutics enters into $21M common stock purchase agreement - Leap Therapeutics has entered into common stock purchase agreements for up to $21M with Lincoln Park Capital Fund, a Chicago-based institutional investor and current shareholder. LPC agreed to purchase $1M of Leap's registered common stock at a price of $1.75 per share. Net proceeds to the company are approximately $950K. Under the terms of a separate common stock purchase agreement, Leap will have the option, but not the obligation, to sell to LPC up to an additional $20M in shares of common stock in tranches over a twenty-four month period and once a registration statement relating to the transaction is declared effective. There is no upper limit as to the price per share that LPC may pay for future stock issuances under the Commitment Purchase Agreement, and Leap will control the timing and amount of any future sales. LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Leap's common stock. In consideration for entering into the Commitment Purchase Agreement and in lieu of making a cash payment, Leap has issued 330,000 shares of common stock to LPC. Leap maintains the right to terminate the Commitment Purchase Agreement at any time, at its discretion.

08:03 EDT GameStop announces preliminary results of modified Dutch auction tender offer - GameStop announced the preliminary results of its "modified Dutch auction" tender offer to purchase up to 12,000,000 shares of its Class A common stock, par value $0.001 per share. The tender offer expired at 5:00 p.m., New York City time, on July 10, 2019. In accordance with the terms and conditions of the tender offer and based on the preliminary count by Computershare Trust Company, N.A., the depositary for the tender offer, GameStop expects to accept for payment, at a purchase price of $5.20, a total of 12,000,000 shares properly tendered at the purchase price and not properly withdrawn before the expiration date, at an aggregate cost of approximately $62,400,000, excluding fees and expenses relating to the tender offer. GameStop expects to accept the shares on a pro rata basis, except for tenders of "odd lots," which will be accepted in full and conditional tenders that will automatically be regarded as withdrawn because the condition of the tender has not been met, and has been informed by the depositary that the preliminary proration factor for the tender offer is approximately 41.3%. The shares expected to be purchased represent approximately 11.72% of GameStop's Class A common stock issued and outstanding as of July 10, 2019.

08:03 EDT iCAD receives CE Mark approval for ProFound AI for 2D Mammography - iCAD announced its advanced artificial intelligence technology and workflow solution, ProFound AI for 2D Mammography, received CE Mark approval. The technology is the latest addition to iCAD's deep-learning ProFound AI platform, joining ProFound AI for Digital Breast Tomosynthesis, which was CE Marked in March 2018, FDA-cleared in December 2018, and Health Canada licensed in July 2018. The technology was developed to support the detection of breast cancer through the identification of soft tissue densities and calcifications.

08:02 EDT Legg Mason reports preliminary AUM $780.2B as of June 30 - This month's AUM included long-term net inflows of $0.5B, driven by fixed income inflows of $0.8B and alternative inflows of $0.2B, partially offset by equity outflows of $0.5B. Alternative AUM reflected $0.2B of realizations. AUM also included a positive foreign exchange impact of $1.2B and liquidity net inflows of $0.1B.

07:48 EDT Sinclair Broadcast reports preliminary Q2 media revenue approximately $721M - Sinclair Broadcast (SBGI) released preliminary Media Revenues for the three months ended June 30, of approximately $721M, which is in line with the company's previously released outlook of $716M-$725M. The company also announced that it has entered into a multi-year agreement with Charter Communications (CHTR) for the continued carriage of the company's broadcast television stations and Tennis Channel, as well as carriage of Marquee Sports Network when it launches in the first quarter of 2020. The agreement also provides for a term extension for the carriage of currently carried FOX (FOX) regional sports networks that is effective upon the company closing on its pending acquisition of the RSNs from the Walt Disney Company (DIS).

07:43 EDT Sinclair Broadcast reports preliminary Q2 media revenue approximately $721M - Sinclair Broadcast released preliminary Media Revenues for the three months ended June 30, of approximately $721M, which is in line with the company's previously released outlook of $716M-$725M. The company also announced that it has entered into a multi-year agreement with Charter Communications (CHTR) for the continued carriage of the company's broadcast television stations and Tennis Channel, as well as carriage of Marquee Sports Network when it launches in the first quarter of 2020. The agreement also provides for a term extension for the carriage of currently carried FOX regional sports (FOX) networks that is effective upon the company closing on its pending acquisition of the RSNs from the Walt Disney Company (DIS).

07:40 EDT Eldorado Resorts to sell two casinos to Twin River Worldwide for $230M - Eldorado Resorts (ERI) announced that it has entered into a definitive agreement to sell Isle of Capri Casino Kansas City in Kansas City, Missouri and Lady Luck Casino Vicksburg in Vicksburg, Mississippi to Twin River Worldwide (TRWH) for aggregate consideration of $230M in cash, subject to a working capital adjustment. Eldorado expects to use the net proceeds from the transaction for general corporate purposes, including for the proposed acquisition of Caesars (CZR) announced June 24. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close in early 2020.

07:36 EDT Biohaven Pharmaceutical's rimegepant featured in 16 presentations at AHS meeting - Biohaven Pharmaceutical will present 16 scientific presentations highlighting new efficacy and safety data for rimegepant from Biohaven's clinical development program at the American Headache Society Annual Scientific Meeting in Philadelphia, July 11-14. Biohaven will be presenting results from the rimegepant Zydis oral fast-dissolve tablet Phase 3 trial, new analyses across the three Phase 3 trials, results from the rimegepant long-term safety study, and new clinical pharmacology data. Rimegepant is an oral, single dose, selective and potent small molecule calcitonin gene-related peptide receptor antagonist in development for the acute treatment of migraine. Consistent with the two previous Phase 3 clinical trials for rimegepant oral tablet, Study 303 met its co-primary endpoints of pain freedom and freedom from the most bothersome symptom at two hours using a single dose. Importantly, patients treated with the rimegepant Zydis ODT formulation began to experience pain relief as early as 15 minutes, with numerical separation from placebo, and this difference was statistically significant at 60 minutes. Additionally, a significantly greater percentage of patients treated with rimegepant Zydis ODT returned to normal functioning by 60 minutes as compared to placebo. Sustained clinical benefit was observed through 48 hours after a single dose of rimegepant. The co-primary endpoints achieved in all three Phase 3 trials are consistent with regulatory guidance from the FDA for NDA submissions.

07:35 EDT Theratechnologies board authorizes management to apply for NASDAQ listing - The Company confirmed that its Board of Directors has authorized management to apply for the listing of its common shares on NASDAQ. Required documentation will be prepared and should be filed over the next few weeks.

07:33 EDT Cronos Group to acquire fermentation, manufacturing facility in Winnipeg - Cronos Group announced that it has entered into an agreement to acquire an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada from Apotex Fermentation. The state-of-the-art facility, which will operate as "Cronos Fermentation", includes fully equipped laboratories covering microbiology, organic and analytical chemistry, quality control and method development as well as two large scale microbial fermentation production areas with combined production capacity of 102,000L, three downstream processing plants, and bulk product and packaging capabilities. As previously announced, Cronos Group has entered into a partnership with Ginkgo Bioworks to produce cultured cannabinoids. Research and development under this partnership is progressing, and as associated milestones are hit, this new facility is expected to provide Cronos Group with the ability to produce cultured cannabinoids at commercial scale with high-quality and high-purity. The acquisition is expected to close in the third quarter of 2019, subject to customary closing conditions. AFI is currently overseeing a wind-down of the facility, which is expected to continue through Fall 2019. During this time, Cronos Group will also begin aligning specifications for the equipment and manufacturing required for the production and downstream processing of cannabinoids. To support this work, Cronos Group expects a team of engineers, scientists, production and quality assurance personnel currently working at the facility to join Cronos Group. Commercial production at the facility is subject to completion of the equipment alignment for cannabinoid based production, the receipt of the appropriate licenses from Health Canada for the production of cultured cannabinoids under the Cannabis Act and the achievement of milestones under the Ginkgo partnership. The Company intends to use existing cash on hand to fund the acquisition, which is not expected to be material to Cronos Group's cash position.

07:27 EDT Fastenal down 6% to $29.39 after Q2 results miss estimates

07:23 EDT SSR Mining reports Q2 gold equivalent production of over 98,000 oz. - SSR Mining reports Q2 operating results at its three mines. Q2 operating highlights include: the company is on track for higher annual gold production: produced over 98K consolidated gold equivalent ounces from its three operations in Q2 and over 210K gold equivalent ounces year-to-date. At Marigold, production was 54,922 ounces of gold and 7.1 million tonnes of ore were stacked at a gold grade of 0.38 g/t, both a quarter-on-quarter increase. At Seabee, increased gold grade and recovery led to 26,539 ounces of gold production. At Puna, mMining activities achieved planned rates, with silver production of 1.5 million ounces. In Q2, the Marigold mine produced 54,922 ounces of gold, a 3% increase from Q1 mainly due to higher gold grade and ore mined, which was stacked on lower areas of the leach pads. Gold sales totaled 59,703 ounces, 8% higher than the previous quarter.

07:20 EDT HEXO Corp to transfer listing to the New York Stock Exchange - HEXO Corp announced it has received approval from the New York Stock Exchange to transfer the listing of its common shares from the NYSE American to the NYSE. HEXO expects to begin trading on the NYSE effective at the open of markets on July 16, 2019. HEXO's shares will trade on the NYSE under the ticker symbol "HEXO", the same symbol the Company's common shares currently trade under on the NYSE-A, as well as the Toronto Stock Exchange. HEXO's shares will continue to trade on the TSX under such symbol. In connection with the listing of its common shares on the NYSE, the Company will voluntarily delist its common shares from the NYSE-A.

07:18 EDT Delta Air Lines reports Q2 TRASM, adjusted up 3.8% y/y - Reports Q2 adjusted: CASM-Ex up 1.4%; Q2 operating margin up 15.5%, Q2 free cash flow up 27.2%.

07:16 EDT Village Farms reports Pure Sunfarms hemp production at full run-rate - Village Farms announced that its 50%-owned joint venture for large-scale cannabis production, Pure Sunfarms, has, on schedule, achieved full run-rate production of 75K kilograms of dried cannabis annually at its 1.1 million square foot Delta 3 greenhouse in Delta, B.C. CEO Michael DeGiglio stated, "We look forward to strong growth in revenue and profitability at Pure Sunfarms, driven by the successful ramp to full production at Delta 3. In addition, gross margin will benefit from the start of sales to the Ontario Cannabis Store and other potential retailers following Health Canada's expected near-term approval to sell directly to provincial/territorial and private retailers, as well as the transition of Pure Sunfarms' supply agreement with another licensed producer to more favorable terms on January 1, 2020." Pure Sunfarms continues to steadily progress on its in-house extraction capabilities, which it expects to be operational this year. Pure Sunfarms has commenced conversion of its second 1.1 million square foot greenhouse operation, Delta 2, for cannabis production, which will double Pure Sunfarms' annual output at full production to 150,000 kilograms. Pure Sunfarms expects to complete its first harvest at the Delta 2 facility by mid-2020, ramp to full run rate annual production by the fourth quarter of 2020, and operate at full production of 75,000 throughout 2021.

07:12 EDT Delta Air Lines CFO says 'solid line of sight' to achieve 1% cost growth target - "With efficiency gains from our operations, fleet transformation, and One Delta initiatives, we have solid line of sight to achieve our 1% cost growth target for the year," said Paul Jacobson, Delta's CFO. "Our strong financial foundation and cash generation allow us to sustainably invest in the business, while maintaining our investment grade balance sheet and consistently returning cash to shareholders. With our cash flow exceeding original expectations, we are on track to return $3 billion to our owners this year through share repurchases and our increased dividend."

07:11 EDT Main Street exits portfolio investment in Lamb Ventures - Main Street recently fully exited its debt and equity investments in Lamb Ventures upon the sale of Lamb's to a sponsor-backed strategic acquirer. Founded in 1987 and headquartered in Austin, Texas, Lamb's operates 18 tire and automotive repair retail locations throughout the greater Austin area. Main Street realized a gain of $6.0M on the exit of its equity investment in Lamb's, with this realized value representing an increase in value of $0.1M above Main Street's fair market value of this investment as of March 31. On a cumulative basis since Main Street made its initial investment in 2008, Main Street realized an annual internal rate of return of 11.0% and a 2.2x times money invested return on its cumulative debt and equity investments in Lamb's.

07:08 EDT Plug Power announces expanded contract with FM Logistic - Plug Power announced an expanded contract with FM Logistic, making it the first traditional GenKey customer in Europe. FM Logistic initially adopted Plug Power's GenDrive hydrogen fuel cell technology in 2015. The expanded relationship will include an increased fleet of GenDrive fuel cells along with a GenFuel hydrogen refueling station - Plug Power's first in Europe - which will supply FM Logistic's hydrogen capacity over the next five years. The new contract was signed in May 2019 and will include all necessary refueling infrastructure, related services, and hydrogen fuel. The new hydrogen refueling station will be located at FM Logistic's operation in Neuville aux Bois, France.

07:08 EDT Delta Air Lines raises quarterly dividend 15% to 40.25c per share - This marks the sixth consecutive increase in Delta's dividend since it was established in 2013. The September quarter dividend will be payable to shareholders of record as of the close of business on July 25 to be paid on August 15.

07:06 EDT Aleafia Health added to NYSE-listed The Cannabis ETF - Aleafia Health has been added to The Cannabis ETF, which trades on the New York Stock Exchange. THCX seeks to track the Innovation Labs Cannabis Index which is a portfolio of 35 stocks expected to benefit from growth of the legal marijuana, CBD and hemp industries.

07:05 EDT Asanko Gold appoints Josephat Zvaipa as EVP, COO - Asanko Gold (AKG) announces changes to its senior management team following a review of the current business needs as managers and operators of the Asanko Gold Mine in Ghana, West Africa. The AGM is owned by Asanko Gold Ghana Limited. AGGL is 90% owned by a 50:50 Joint Venture between the Company and Gold Fields Limited (GFI) and 10% owned by the Government of Ghana. These changes will better align the business to the strategy of maximizing the benefits of the recent major capital investments at the AGM as the focus shifts to cash flow generation. Effective August 1, 2019, Josephat Zvaipa will be appointed EVP & COO based in the Company's Johannesburg office. Joe currently acts as chairman of the Management Committee of the Joint Venture and will continue to manage the operations as well as joint venture relations in his new role, reporting to the CEO. For the past four years, Joe has been the Company's Managing Director, Ghana. The move follows the recent appointment of Frederick Attakumah, previously SVP - corporate affairs and sustainability, as EVP and Managing Director of AGGL. In conjunction with the change, Peter Breese will be retiring from his management and board roles with the Company. The Company's technical services group, based in Johannesburg, will continue to support the AGM operations with long-range mine planning, resource estimation, capital project management, exploration planning and engineering. The group will be consolidated and managed by Asanko's current SVP Mineral Resources, Mike Begg, in a newly created role of SVP Technical Services, reporting to the CEO The roles of EVP Strategy, SVP Organisational Capability, SVP Metallurgy and SVP Projects have been made redundant effective July 31, 2019.

07:05 EDT Delta Air Lines sees Q3 TRASM, adjusted up 1.5%-3.5%, y/y - Sees Q3 CASM-Ex, up 1%-2% y/y. Sees Q3 system capacity up ~4% y/y. Sees Q3 fuel price, including taxes and refinery impact $1.95-$2.15.

07:02 EDT Delta Air Lines raises quarterly dividend 15%

07:01 EDT Delta Air Lines raises FY19 EPS view

06:53 EDT The Buckle reports June comparable store net sales up 6.2% - The Buckle reported comparable store net sales, for stores open at least one year, for the 5-week period ended July 6 increased 6.2% from comparable store net sales for the 5-week period ended July 7, 2018. Net sales for the 5-week fiscal month ended July 6, 2019 increased 5.5% to $74.8M from net sales of $70.9M for the prior year 5-week fiscal month ended July 7, 2018. Comparable store net sales year-to-date for the 22-week period ended July 6, 2019 increased 0.4% from comparable store net sales for the 22-week period ended July 7, 2018. Net sales for the 22-week fiscal period ended July 6, 2019 decreased 0.1% to $337.6M from net sales of $338.0M for the prior year 22-week fiscal period ended July 7, 2018.

06:51 EDT Fastenal reports Q2 daily sales up 7.9%

06:49 EDT Kennametal initiates restructuring actions - Kennametal announced several restructuring actions that would facilitate a simplified and leaner structure, while further positioning the company for long-term profitable growth. As part of its ongoing simplification/modernization initiative, the company is optimizing its operations globally, including footprint rationalization. The company's proposal is to close its manufacturing facilities in Essen and Lichtenau as well as its distribution center in Neunkirchen, all in Germany. Additionally, the company announced its decision to close its manufacturing facility in Irwin, PA. These restructuring actions advance the company toward the fiscal 2021 financial targets announced at its most recent Investor Day. They are also part of the previously announced goal of reducing plants through simplification/modernization, with additional plants currently under evaluation. The proposed restructurings are expected to be executed over the next two years. Facility closures in fiscal 2020 are part of the current restructuring action, which in total are expected to deliver estimated annualized savings of $35M-$40M and $55M-$65M in pre-tax charges. Fiscal 2021 closures would result in further structural cost reductions with estimated annualized savings of $25M-$30M. Most of these savings will be achieved in fiscal 2021 with full run rate savings being realized in fiscal 2022. The company is expected to incur pre-tax charges of $60M-$75M through fiscal 2020 and 2021 for this restructuring. These charges are primarily cash with the majority being spent in fiscal 2021. Under the proposed measures, the company would consolidate its Essen and Lichtenau operations, including both Kennametal and WIDIA branded products, into other lower-cost Kennametal Industrial facilities. The Irwin operations would be consolidated primarily into the newly modernized Infrastructure plant in Rogers, AR. Kennametal also proposed plans to outsource the distribution operations in its Neunkirchen and Essen facilities to a third-party logistics specialist. The closure plans are contingent on the negotiations with the relevant employee representatives. The company will continue to maintain a strong presence in Germany, including planned modernization investments in other Kennametal locations in the country.

06:45 EDT Waddell & Reed reports preliminary AUM $71.9B as of June 30 - Compared to $68.6B on May 31.

06:35 EDT Kroger, Ocado announce plans for $55M customer fulfillment center in Georgia - Kroger (KR) and Ocado (OCDGF) announced plans for a new customer fulfillment center, or CFC, in Forest Park, Georgia, a $55M investment that will create more than 400 new jobs. Kroger has committed to building 20 CFCs, powered by Ocado. The CFC model, an automated warehouse facility with digital and robotic capabilities, will be replicated to serve customers across America. Last month, Kroger broke ground on America's first CFC, which is being constructed in Monroe, Ohio. The CFC is scheduled to break ground later this year and be operational in 2021.

06:32 EDT Air Lease announces lease, delivery of two Airbus A321-200s to Air Canada - Air Lease (AL) announced the lease and delivery of two Airbus (EADSY) A321-200 aircraft to Air Canada.

06:03 EDT Cenovus Energy gets 1B barrels of production from Foster Creek, Christina Lake - Cenovus Energy announced that on July 10, the company reached 1B barrels of cumulative production from its Foster Creek and Christina Lake oil sands facilities in northern Alberta. Cenovus is the first company to produce one billion barrels of oil using steam-assisted gravity drainage technology. Foster Creek began producing oil as a pilot under a predecessor company in 1997 and in 2001 became the first commercial oil sands project to use SAGD, while Christina Lake began producing oil in 2002

05:10 EDT ExlService enters partnership with British Friendly - EXL announced it will partner with UK mutual insurer British Friendly "to develop an end-to-end customer on-boarding, underwriting and policy administration platform." The digital platform will improve efficiencies for advisers when placing clients on risk and accelerate the ability of British Friendly to respond to changing consumer requirements and bring new products to market.